Associate Director, Toxicological Pathologist

Cambridge, MA, United States
Nov 08, 2020
Required Education
Bachelors Degree
Position Type
Full time
Our mission:

Developing curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

At Intellia, we are committed to solving the complex challenges of making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to create novel engineered cell therapies for immuno-oncological and autoimmune diseases.

Intellia Therapeutics is seeking to support an expanding development pipeline with scientists to characterize the safety of their innovative products. We are currently seeking an Associate Director to serve as Pathology Lead. Ideal candidates will be enthusiastic, entrepreneurial scientists motivated to shape how gene editing benefits patients. The successful candidate will have opportunities to lead basic research initiatives while gaining broad experience supporting nonclinical development of CRISPR/Cas9 products.

    • Contributes to the overall toxicology strategy for one or several Research and Development programs, throughout the drug development lifecycle
    • Interacts with other functional area experts in a project team environment to recommend the best course of action for a given program, and defend those recommendations to internal governance committees
    • Scientifically oversee the design, reporting and interpretation of exploratory and GLP-compliant outsourced safety studies; serve as study monitor and/or peer review pathologist; prepared to support the execution of each study
    • Reviews study designs and ensures interdependencies (e.g., Bioanalytical, CMC and Quality and Clinical) are aligned with emphasis on the appropriate and efficient evaluation of pathology
    • Represents Intellia on partnered programs and at external venues such as scientific meetings
    • Succinctly and effectively summarizes the content and safety implications from nonclinical studies for regulatory submissions, including components for IBs and clinical protocols
    • Interact with Health Authorities, in writing and verbally, including pre-IND or scientific advice filings, IND or CTA, meeting briefing books, or other requests from global regulatory authorities.

Basic Qualifications:
    • DVM/VMD and unrestricted licensure
    • Board certification veterinary anatomical pathology or AP/CP
    • Experience with ICH guided, GLP compliant nonclinical study design and conduct, including pathology peer review
    • Experience managing multiple drug development programs and priorities, studies, external CRO management
    • Solid understanding of molecular biology, genetics and immunology

Preferred Qualifications:
    • Board certifications in clinical pathology and/or toxicology provide additional consideration
    • Expertise in immunotoxicology, immunogenicity, T cell biology
    • Experience with lipid nanoparticle delivery of nucleic acid therapies
    • Experience with development of Cell and Gene Therapy or ATMP products, and bioassay requirements
    • Understanding of the evolving regulatory requirements for cell and gene therapy (CBER/OTAT) products in the US or ATMP products in Europe.
    • Experience in oncology and/or rare disease drug discovery
    • Prior experience in cell therapy preferred, though experience in other treatment modalities in oncology such as antibody therapeutics would also be valuable
    • Detailed knowledge of cellular and/or tumor immunology principles, technologies, and experimental techniques (cell culture, in vitro cellular assays, flow cytometry)
    • Expertise in functional assays measuring cellular activation, cytokine release, proliferation, and cell killing.


What Intellia Stands For:

We push boundaries. We are focused on positively disrupting health care treatment of patients with genomic diseases. The values we live by and drivers we look for are:

- One is respect for individuals; our unique qualities and strengths; our own ways to understand, learn and improve. One is our single-minded determination to excel; to succeed together. One is you and us - trusting and counting on every single one of us.

- Explore because we seek new ways to tackle disease. Explore with unbounded from assumptions, open to ideas. Explore by staying curious, by pushing boundaries, overcoming obstacles. Explore means thinking of new ways.

- Disrupt by thinking courageously...and creating a better future. Disrupt by defying conformity; interrogating the status quo; questioning our momentum. Disrupt with challenging thoughts...with that breed of skepticism that shows you have better solutions.

- Deliver with your focus on the objective and your determination to complete the task. Deliver by advancing relentlessly and by maintaining high standards...even when nobody is watching. Deliver by staying accountable and pulling your weight. Deliver because patients are counting on us to make the promise reality. Get it done.

POSITION: Full-Time, Exempt

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Intellia's web-based application process is managed through Lever. Information submitted through application forms is collected by Lever and subject to Lever's privacy policy .